PNC Financial Services Group
INDP icon

PNC Financial Services Group’s Indaptus Therapeutics INDP Stock Holding History

PNC Financial Services Group’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-33
Closed -$424K – 4102
2018
Q3 		$424K Buy
33
+11
+50% +$105K ﹤0.01% 1768
2018
Q2 		$220K Buy
+22
New +$244K ﹤0.01% 2132

Other funds holding INDP

MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return

PNC Financial Services Group's INDP Position: Q4 2018 in Review

PNC Financial Services Group sold out of Indaptus Therapeutics (INDP) in Q4 2018, closing a stake of 33 shares — an estimated $424K sold.

PNC Financial Services Group first reported a position in INDP in Q2 2018 and held it in 2 quarters. The position peaked at $424K in Q3 2018. 30 funds tracked by Wall St. Rank hold INDP as of Q4 2018.

  • PNC Financial Services Group reported no remaining Indaptus Therapeutics position as of Q4 2018 after selling out during the quarter.
  • PNC Financial Services Group sold 33 Indaptus Therapeutics shares in Q4 2018, an estimated $424K.
  • PNC Financial Services Group first reported a position in Indaptus Therapeutics in Q2 2018 and held it in 2 quarters.
  • PNC Financial Services Group's Indaptus Therapeutics position peaked at $424K in Q3 2018.
  • 30 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q4 2018.

Based on PNC Financial Services Group's 13F filing for Q4 2018, filed 8 Feb 2019.